Related references
Note: Only part of the references are listed.SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Manit Munshi et al.
BLOOD CANCER JOURNAL (2020)
Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study
Roger G. Owen et al.
LANCET HAEMATOLOGY (2020)
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
Steven E. Coutre et al.
BLOOD ADVANCES (2019)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia
Zachary R. Hunter et al.
BLOOD ADVANCES (2018)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
CXCL13 levels are elevated in patients with Waldenstrom macroglobulinemia, and are predictive of major response to ibrutinib
Josephine M. Vos et al.
HAEMATOLOGICA (2017)
Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
CXCL13 levels are elevated in patients with Waldenstrom macroglobulinemia, and are predictive of major response to ibrutinib
Josephine M. Vos et al.
HAEMATOLOGICA (2017)
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E. Wiczer et al.
BLOOD ADVANCES (2017)
Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia
Lian Xu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2016)
Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia
Joshua N. Gustine et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Guang Yang et al.
BLOOD (2016)
Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia
Veronique Leblond et al.
BLOOD (2016)
MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenstrom macroglobulinaemia cells
Yang Cao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia
Y. Cao et al.
LEUKEMIA (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
Aldo M. Roccaro et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
Guang Yang et al.
BLOOD (2013)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenstrom Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel et al.
BLOOD (2009)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)